Nothing Special   »   [go: up one dir, main page]

SG11201408787PA - Enhancing activity of car t cells by co-introducing a bispecific antibody - Google Patents

Enhancing activity of car t cells by co-introducing a bispecific antibody

Info

Publication number
SG11201408787PA
SG11201408787PA SG11201408787PA SG11201408787PA SG11201408787PA SG 11201408787P A SG11201408787P A SG 11201408787PA SG 11201408787P A SG11201408787P A SG 11201408787PA SG 11201408787P A SG11201408787P A SG 11201408787PA SG 11201408787P A SG11201408787P A SG 11201408787PA
Authority
SG
Singapore
Prior art keywords
international
car
llll
iii
bispecific antibody
Prior art date
Application number
SG11201408787PA
Inventor
Carl H June
Yangbing Zhao
Xiaojun Liu
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201408787PA publication Critical patent/SG11201408787PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 January 2014 (16.01.2014) WIPOIPCT (10) International Publication Number WO 2014/011988 A3 (51) International Patent Classification: C07K14/05 ( 2006.01) (21) International Application Number: PCT/US2013/050275 (22) International Filing Date: 12 July 2013 (12.07.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/671,535 13 July 2012 (13.07.2012) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Center For Technology Transfer, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6283 (US). (72) Inventors: JUNE, Carl, H.; 409 Baird Road, Merion Sta­ tion, PA 19066 (US). ZHAO, Yangbing; 23 Doncaster Rd„ Cherry Hill, NJ 08003 (US). LIU, Xiaojun; 801 Yale Avenue, Apt. 809, Swarthmore, PA 19081 (US). (74) Agents: NGUYEN, Quang D. et al.; Riverside Law, LLP, 300 Four Falls Corporate Center, Suite 710, 300 Consho- hocken State Road, West Conshohocken, PA 19428 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [Continued on next page] (54) Title: ENHANCING ACTIVITY OF CAR T CELLS BY CO-INTRODUCING A BISPECIFIC ANTIBODY CMS VR CtSSVtJ CS3VH !)} (57) Abstract: The present invention provides compositions and methods for treating cancer in human. The invention includes administering a a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a hu­ manized antibody, or antigen-binding fragments thereof. pGEM-2304(CD39)B62.64A ; CDSMse&IM f P®lyAT«1 pt»H<?8(Ct>»5-8BZ.64A w» < oo 00 0\ *1 ; Figure 1 WO 2014/011988 A3 III llll IIII III III Hill III III III Hill lllll lllll lllll llll 111 mill llll 111 llll (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 13 March 2014
SG11201408787PA 2012-07-13 2013-07-12 Enhancing activity of car t cells by co-introducing a bispecific antibody SG11201408787PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671535P 2012-07-13 2012-07-13
PCT/US2013/050275 WO2014011988A2 (en) 2012-07-13 2013-07-12 Enhancing activity of car t cells by co-introducing a bispecific antibody

Publications (1)

Publication Number Publication Date
SG11201408787PA true SG11201408787PA (en) 2015-01-29

Family

ID=49916699

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408787PA SG11201408787PA (en) 2012-07-13 2013-07-12 Enhancing activity of car t cells by co-introducing a bispecific antibody

Country Status (15)

Country Link
US (4) US9765156B2 (en)
EP (2) EP2872526B1 (en)
JP (1) JP2015524255A (en)
KR (1) KR20150029714A (en)
CN (1) CN104583230A (en)
AU (1) AU2013289971A1 (en)
BR (1) BR112015000638A2 (en)
CA (1) CA2876730A1 (en)
EA (1) EA201590208A1 (en)
ES (1) ES2786263T3 (en)
HK (1) HK1207090A1 (en)
IL (1) IL236337A0 (en)
MX (1) MX2015000426A (en)
SG (1) SG11201408787PA (en)
WO (1) WO2014011988A2 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111139256A (en) 2013-02-20 2020-05-12 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
ES2681948T3 (en) * 2013-03-05 2018-09-17 Baylor College Of Medicine Coupling cells for immunotherapy
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
US9890393B2 (en) 2013-05-29 2018-02-13 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
BR112016013187A2 (en) 2013-12-19 2017-09-26 Novartis Ag human mesothelin chimeric antigen receptors and their uses
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
WO2015112626A1 (en) * 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
ES2959480T3 (en) * 2014-02-07 2024-02-26 Univ Mcmaster T cell coupler - trifunctional antigen and methods and uses thereof
US10836998B2 (en) 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
PL3129470T3 (en) 2014-04-07 2021-11-29 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CA2955465A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
CN112481283A (en) 2014-07-21 2021-03-12 诺华股份有限公司 Treatment of cancer using CD33 chimeric antigen receptor
RU2751660C2 (en) 2014-07-21 2021-07-15 Новартис Аг Treatment of malignant neoplasm using humanized chimeric antigen receptor against bcma
CN112410363A (en) 2014-08-19 2021-02-26 诺华股份有限公司 anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy
KR20230149327A (en) 2014-09-17 2023-10-26 노파르티스 아게 Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
IL279420B2 (en) 2014-10-08 2024-09-01 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
DK3207130T3 (en) 2014-10-14 2019-11-11 Halozyme Inc Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof, and Methods for Using the Same
KR20170074243A (en) * 2014-10-31 2017-06-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Methods and compositions for modified t cells
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
JP7068820B2 (en) 2014-12-03 2022-05-17 ジュノー セラピューティクス インコーポレイテッド Methods and Compositions for Adoptive Cell Therapy
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US20170362297A1 (en) * 2014-12-19 2017-12-21 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
ES2976197T3 (en) 2014-12-24 2024-07-26 Autolus Ltd Cell
RU2021118125A (en) 2014-12-29 2022-04-06 Новартис Аг METHODS FOR OBTAINING EXPRESSING CHIMERIC ANTIGENIC RECEPTOR CELLS
US11382963B2 (en) 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
US20180002427A1 (en) 2015-01-26 2018-01-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
CA2975147A1 (en) 2015-01-31 2016-08-04 Yangbing Zhao Compositions and methods for t cell delivery of therapeutic molecules
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL303972A (en) * 2015-04-08 2023-08-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN105158466B (en) * 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 A kind of method of Chimeric antigen receptor T cell for detecting anti-CD19 to leukaemia cyto-inhibition
CN107995913B (en) 2015-05-18 2022-02-11 T细胞受体治疗公司 Compositions and methods for reprogramming TCRs using fusion proteins
CN107708741A (en) * 2015-06-12 2018-02-16 免疫医疗公司 The physics carried out with the T cell (CAR T) or NK cells (CAR NK) of Chimeric antigen receptor (CAR) construct and expression CAR constructs
MA42902A (en) * 2015-07-08 2018-05-16 Univ Johns Hopkins MARINAL-INFILTRATING LYMPHOCYTES (MIL) AS A SOURCE OF T-LYMPHOCYTES FOR CHEMERIC ANTIGEN RECEPTOR (CAR) THERAPY
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
WO2017011728A1 (en) * 2015-07-15 2017-01-19 Washington University ANTIBODIES TO TUMOR ASSOCIATED COMPLEX N-GLYCANS WITH TERMINAL GlcNAcBeta RESIDUES AND METHODS OF USE THEREOF
CA2992551A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN105384825B (en) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
JP2018522907A (en) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017040195A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108780084B (en) 2015-09-03 2022-07-22 诺华股份有限公司 Biomarkers predictive of cytokine release syndrome
CN114470193B (en) * 2015-10-13 2024-08-30 优瑞科生物技术公司 Antibody agents specific for human CD19 and uses thereof
IL258405B (en) 2015-10-23 2022-09-01 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
SG10201912825XA (en) * 2015-11-27 2020-02-27 Cartherics Pty Ltd Genetically modified cells and uses thereof
EP3383892B1 (en) * 2015-12-03 2022-12-21 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CN109069597A (en) 2015-12-22 2018-12-21 诺华股份有限公司 Mesothelin Chimeric antigen receptor (CAR) and the combination of anti-PD-L1 antibody inhibition are in anticancer therapy
US20190269727A1 (en) * 2015-12-28 2019-09-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20200370011A1 (en) * 2016-01-08 2020-11-26 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Geriatric car-t cells and uses thereof
DK3405490T3 (en) 2016-01-21 2022-01-10 Pfizer MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF
EA201891641A1 (en) * 2016-01-21 2019-01-31 Пфайзер Инк. CHEMICAL ANTIGENOUS RECEPTORS AIMED AT OPTION III RECEPTOR EPIDERMAL GROWTH FACTOR
WO2017165683A1 (en) * 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US20190105348A1 (en) * 2016-04-08 2019-04-11 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AR110676A1 (en) 2016-10-07 2019-04-24 Novartis Ag TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
MX2019003899A (en) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins.
CN110177803A (en) 2016-11-22 2019-08-27 T细胞受体治疗公司 For using fusion protein to carry out the composition and method that TCR is reprogramed
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
US20200165342A1 (en) * 2017-02-21 2020-05-28 Eutilex Co., Ltd. Hla-dr car-t compositions and methods of making and using the same
JP7178355B2 (en) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Compositions and methods for CAR T cell therapy
EP3595721A4 (en) 2017-03-16 2021-01-06 The General Hospital Corporation Chimeric antigen receptors targeting cd37
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
CN108727497A (en) * 2017-04-17 2018-11-02 沈阳美达博生物科技有限公司 A kind of CD19 antibody and its application
WO2018199593A1 (en) * 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Bispecific antibody binding to her3 and cd3
SG10201913579WA (en) 2017-04-26 2020-02-27 Eureka Therapeutics Inc Chimeric antibody/t-cell receptor constructs and uses thereof
CN107267555B (en) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 Malignant glioma CAR-T therapeutic vector based on OCTS technology and construction method and application thereof
TWI778068B (en) * 2017-06-02 2022-09-21 美商輝瑞大藥廠 Chimeric antigen receptors targeting flt3
US20220233588A1 (en) 2017-06-30 2022-07-28 Cellectis Cellular immunotherapy for repetitive administration
WO2019032699A1 (en) * 2017-08-09 2019-02-14 Eureka Therapeutics, Inc. Cells expressing cell surface receptors and antibodies
CN109422815A (en) * 2017-08-28 2019-03-05 复旦大学 Bispecific chimeric antigen receptor c-Met/PD-1 scFv-CAR-T and its construction method and application
CN111148533A (en) 2017-09-19 2020-05-12 麻省理工学院 Compositions for chimeric antigen receptor T cell therapy and uses thereof
CN111479925B (en) 2017-10-12 2024-03-08 麦克马斯特大学 T cell-antigen conjugates with Y182T mutations and methods and uses thereof
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
CN109706120A (en) * 2017-10-26 2019-05-03 深圳宾德生物技术有限公司 A kind of double target spot T lymphocyte specifics and its preparation method and application
JP7080514B2 (en) * 2017-12-22 2022-06-06 アブクロン・インコーポレイテッド Antibodies that specifically recognize malignant B cells or antigen-binding fragments thereof, chimeric antigen receptors containing them and their uses
CN109971717B (en) * 2017-12-28 2023-06-20 上海细胞治疗研究院 T cells co-expressing CD40 antibody and mesothelin specific chimeric antigen receptor and uses thereof
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
CN109988242A (en) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 Joint Chimeric antigen receptor, expression vector, slow virus and T cell
CN108285486A (en) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 Using CD20 as the specific antibody of target spot, CAR-NK cells and its preparation and application
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
KR20210018196A (en) * 2018-03-15 2021-02-17 펀다멘탈 솔류션스 코포레이션 Programmable immune cell receptor complex system
MX2020009475A (en) * 2018-03-16 2021-01-15 Cytoimmune Therapeutics Inc Bispecific antibody car cell immunotherapy.
US10869888B2 (en) * 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CN109161532A (en) * 2018-05-31 2019-01-08 华东师范大学 The engineering immunocyte of PSMA and PD-L1 is targeted simultaneously
BR112020025048A2 (en) 2018-06-13 2021-04-06 Novartis Ag BCMA CHEMICAL ANTIGEN RECEPTORS AND USES OF THE SAME
WO2019246546A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MX2021000541A (en) * 2018-07-17 2021-08-16 Triumvira Immunologics Usa Inc T cell-antigen coupler with various construct optimizations.
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
EP3826625A4 (en) 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN110872356B (en) * 2018-09-03 2023-06-13 广西慧宝源健康产业有限公司 Bispecific antibodies and methods of use thereof
WO2020061796A1 (en) * 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
WO2020068261A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
CN109575143B (en) * 2018-12-29 2022-06-17 博生吉医药科技(苏州)有限公司 Bispecific CD20-CD19-CAR and application thereof
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP2022538974A (en) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4028414A4 (en) 2019-09-11 2024-01-17 The Trustees of The University of Pennsylvania Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars)
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
KR20220104217A (en) 2019-11-26 2022-07-26 노파르티스 아게 CD19 and CD22 chimeric antigen receptors and uses thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
KR20220166282A (en) 2020-03-10 2022-12-16 매사추세츠 인스티튜트 오브 테크놀로지 Methods for generating engineered memory-like NK cells and compositions thereof
WO2021183207A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
CN111484562B (en) * 2020-04-25 2021-08-20 首都医科大学附属北京朝阳医院 Antibody targeting CD22 protein, chimeric antigen receptor and drug
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021223720A1 (en) * 2020-05-06 2021-11-11 亘喜生物科技（上海）有限公司 Humanized cd19 antibody and use thereof
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
KR20230040333A (en) * 2020-07-16 2023-03-22 난징 레전드 바이오테크 씨오., 엘티디. Multispecific Chimeric Antigen Receptors and Uses Thereof
EP4196579A1 (en) 2020-08-13 2023-06-21 Yale University Compositions and methods for engineering and selection of car t cells with desired phenotypes
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
WO2022111562A1 (en) * 2020-11-26 2022-06-02 上海医药集团生物治疗技术有限公司 Modified immune cell and use thereof
EP4347660A1 (en) 2021-06-01 2024-04-10 Triumvira Immunologics USA, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
KR20240112252A (en) * 2021-08-18 2024-07-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for chimeric antigen receptors specific for B cell receptors
JP2024537991A (en) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド Immune cells with co-expressed shRNAs and logic gate systems
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
CN114133457B (en) * 2021-12-08 2022-08-19 郑州源创吉因实业有限公司 Bispecific Chimeric Antigen Receptor (CAR) targeting ROR1 and CD33 and application thereof
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5504692A (en) 1992-06-15 1996-04-02 E. I. Du Pont De Nemours Co., Inc. System and method for improved flow data reconciliation
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
HU225688B1 (en) * 1995-02-24 2007-06-28 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
IL132062A0 (en) 1997-04-14 2001-03-19 Micromet Ges Fuer Biomedizinis Novel method for the production of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001243288B2 (en) 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
BR0108962A (en) 2000-03-03 2002-12-24 Valentis Inc Nucleic acid formulations for gene distribution and methods of use
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
CN1195779C (en) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 Double-specificity antibody resisting human ovary cancer and human CD3
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
EP1629012B1 (en) * 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
EP1660534A2 (en) 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
EP2295588B1 (en) 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
US20070014720A1 (en) 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
AU2006342101A1 (en) 2005-12-07 2007-10-25 Genetronics, Inc Variable volume electroporation chamber and methods therefore
CN103694349A (en) 2006-09-08 2014-04-02 米迪缪尼有限公司 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
MX350962B (en) 2008-01-07 2017-09-27 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
US8999398B2 (en) * 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
ES2961381T3 (en) * 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
MX340558B (en) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Bispecific antibodies comprising a disulfide stabilized - fv fragment.
NZ612512A (en) 2010-12-09 2015-03-27 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof

Also Published As

Publication number Publication date
HK1207090A1 (en) 2016-01-22
MX2015000426A (en) 2015-07-14
ES2786263T3 (en) 2020-10-09
US20210040234A1 (en) 2021-02-11
US20240018271A1 (en) 2024-01-18
EP2872526A4 (en) 2016-03-23
AU2013289971A1 (en) 2015-01-22
EP2872526B1 (en) 2020-04-01
US9765156B2 (en) 2017-09-19
CA2876730A1 (en) 2014-01-16
US20150322169A1 (en) 2015-11-12
IL236337A0 (en) 2015-02-26
BR112015000638A2 (en) 2017-08-08
US10696749B2 (en) 2020-06-30
US11795240B2 (en) 2023-10-24
CN104583230A (en) 2015-04-29
US20180057609A1 (en) 2018-03-01
EP3730512A1 (en) 2020-10-28
EA201590208A1 (en) 2015-11-30
JP2015524255A (en) 2015-08-24
WO2014011988A3 (en) 2014-03-13
EP2872526A2 (en) 2015-05-20
WO2014011988A2 (en) 2014-01-16
KR20150029714A (en) 2015-03-18

Similar Documents

Publication Publication Date Title
SG11201408787PA (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201810883TA (en) Combination therapy
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201900635QA (en) Chimeric antigen receptors targeting bcma and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201407200TA (en) Liquid formulation
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201805170XA (en) Cellular glycosaminoglycan compositions and methods of making and using
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease